Skinovation Pharmaceutical 10-Q 3 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 03, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-30991
Entity Registrant Name	SKINOVATION PHARMACEUTICAL INCORPORATED
Entity Central Index Key	0001118072
Entity Tax Identification Number	87-0458170
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	2157 S. Lincoln Street
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84106
City Area Code	(801)
Local Phone Number	323-2395
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		708,000

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current Assets
Cash	$ 1,472	$ 222
Total Current Assets	1,472	222
Total Assets	1,472	222
Current Liabilities
Accounts payable	10,500	7,000
Notes payable	249,021	240,021
Accrued interest	145,497	130,793
Total Current Liabilities	405,018	377,814
Total Liabilities	405,018	377,814
Stockholders' Deficit
Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding	708	708
Additional paid-in capital	25,148	25,148
Accumulated deficit	(429,402)	(403,448)
Total Stockholders' Deficit	(403,546)	(377,592)
Total Liabilities and Stockholders' Deficit	$ 1,472	$ 222

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	25,000,000	25,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	50,000,000	50,000,000
Common Stock, Shares, Issued	708,000	708,000
Common Stock, Shares, Outstanding	708,000	708,000

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
General and administrative	2,760	2,800	11,250	11,000
TOTAL EXPENSES	2,760	2,800	11,250	11,000
Loss from operations	(2,760)	(2,800)	(11,250)	(11,000)
OTHER INCOME (EXPENSE)
Interest expense	(4,969)	(4,680)	(14,704)	(13,940)
Total other income (expense)	(4,969)	(4,680)	(14,704)	(13,940)
LOSS BEFORE INCOME TAXES	(7,729)	(7,480)	(25,954)	(24,940)
INCOME TAX EXPENSE
NET LOSS	$ (7,729)	$ (7,480)	$ (25,954)	$ (24,940)
Basic and diluted net loss per share	$ (0.01)	$ (0.01)	$ (0.04)	$ (0.04)
Basic and diluted weighted average shares outstanding	708,000	708,000	708,000	708,000

Condensed Statements of Stockho

Condensed Statements of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance – December 31, 2021 at Dec. 31, 2020	$ 708	$ 25,148	$ (370,998)	$ (345,142)
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	708,000
Net loss			(10,010)	(10,010)
Balance – September 30, 2022 at Mar. 31, 2021	$ 708	25,148	(381,008)	(355,152)
Shares, Outstanding, Ending Balance at Mar. 31, 2021	708,000
Balance – December 31, 2021 at Dec. 31, 2020	$ 708	25,148	(370,998)	(345,142)
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	708,000
Net loss				(24,940)
Balance – September 30, 2022 at Sep. 30, 2021	$ 708	25,148	(395,938)	(370,082)
Balance – December 31, 2021 at Mar. 31, 2021	$ 708	25,148	(381,008)	(355,152)
Shares, Outstanding, Beginning Balance at Mar. 31, 2021	708,000
Net loss			(7,450)	(7,450)
Balance – September 30, 2022 at Jun. 30, 2021	$ 708	25,148	(388,458)	(362,602)
Shares, Outstanding, Ending Balance at Jun. 30, 2021	708,000
Net loss			(7,480)	(7,480)
Balance – September 30, 2022 at Sep. 30, 2021	708	25,148	(395,938)	(370,082)
Balance – December 31, 2021 at Dec. 31, 2021	$ 708	25,148	(403,448)	(377,592)
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	708,000
Net loss			(10,445)	(10,445)
Balance – September 30, 2022 at Mar. 31, 2022	$ 708	25,148	(413,893)	(388,037)
Shares, Outstanding, Ending Balance at Mar. 31, 2022	708,000
Balance – December 31, 2021 at Dec. 31, 2021	$ 708	25,148	(403,448)	(377,592)
Shares, Outstanding, Beginning Balance at Dec. 31, 2021	708,000
Net loss				(25,954)
Balance – September 30, 2022 at Sep. 30, 2022	$ 708	25,148	(429,402)	(403,546)
Shares, Outstanding, Ending Balance at Sep. 30, 2022	708,000
Balance – December 31, 2021 at Mar. 31, 2022	$ 708	25,148	(413,893)	(388,037)
Shares, Outstanding, Beginning Balance at Mar. 31, 2022	708,000
Net loss			(7,780)	(7,780)
Balance – September 30, 2022 at Jun. 30, 2022	708	25,148	(421,673)	$ (395,817)
Shares, Outstanding, Ending Balance at Jun. 30, 2022				708,000
Net loss			(7,729)	$ (7,729)
Balance – September 30, 2022 at Sep. 30, 2022	$ 708	$ 25,148	$ (429,402)	$ (403,546)
Shares, Outstanding, Ending Balance at Sep. 30, 2022	708,000

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows from Operating Activities
Net loss	$ (25,954)	$ (24,940)
Changes in operating assets and liabilities:
Increase in accounts payable	3,500	4,500
Increase in accrued interest	14,704	13,940
Net cash used by operating activities	(7,750)	(6,500)
Cash Flows from Investing Activities
Net cash used by investing activities
Cash Flows from Financing Activities
Proceeds from notes payable	9,000	3,500
Net cash provided by financing activities	9,000	3,500
Net increase (decrease) in cash	1,250	(3,000)
Cash at beginning of period	222	3,552
Cash at end of period	1,472	552
Supplemental Cash Flow Information:
Cash paid for interest
Cash paid for income taxes

NOTE 1 _ CONDENSED FINANCIAL ST

NOTE 1 – CONDENSED FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NOTE 1 – CONDENSED FINANCIAL STATEMENTS	NOTE 1 – CONDENSED FINANCIAL STATEMENTS The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended September 30, 2022 and for all periods presented have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2021 audited financial statements as reported in its Form 10-K. The results of operations for the period ended September 30, 2022 are not necessarily indicative of the operating results for the full year ended December 31, 2022.

NOTE 2 _ GOING CONCERN

NOTE 2 – GOING CONCERN	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NOTE 2 – GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies. The COVID-19 pandemic could have an impact on our ability to obtain financing to fund our operations. The Company is unable to predict the ultimate impact at this time.

NOTE 3 _ ACCOUNTS AND NOTES PAY

NOTE 3 – ACCOUNTS AND NOTES PAYABLE	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
NOTE 3 – ACCOUNTS AND NOTES PAYABLE	NOTE 3 – ACCOUNTS AND NOTES PAYABLE At September 30, 2022 and December 31, 2021, the Company had accounts payable of $ 10,500 7,000 249,021 240,021 8 Accrued interest on the notes was $ 145,497 130,793

NOTE 4 _ SUBSEQUENT EVENTS

NOTE 4 – SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
NOTE 4 – SUBSEQUENT EVENTS	NOTE 4 – SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

NOTE 3 _ ACCOUNTS AND NOTES P_2

NOTE 3 – ACCOUNTS AND NOTES PAYABLE (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Accounts Payable, Current	$ 10,500	$ 7,000
Notes Payable, Current	$ 249,021	240,021
Debt Instrument, Interest Rate During Period	8%
Interest Payable, Current	$ 145,497	$ 130,793